Lyra Therapeutics, a Phase 2 biotech developing an implantable drug-device for chronic rhinosinusitis, raised $56 million by offering 3.5 million shares at $16, the high end of the range of $14 to $16. Lyra Therapeutics plans to list on the Nasdaq under the symbol LYRA. BofA Securities, Jefferies and William Blair acted as lead managers on the deal.
